Skip to main content
GALT
NASDAQ Life Sciences

Director Harold Shlevin files intent to sell $1.84M in GALT shares

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
7
Price
$3.785
Mkt Cap
$244.054M
52W Low
$1.07
52W High
$7.13
Market data snapshot near publication time

summarizeSummary

Director Harold Shlevin filed a Form 144 indicating intent to sell 441,500 shares of Galectin Therapeutics, valued at approximately $1.84 million, following previous sales totaling $1.40 million in the last three months.


check_boxKey Events

  • Director Files Intent to Sell

    Director Harold Shlevin has filed a Form 144, indicating his intent to sell 441,500 shares of common stock.

  • Significant Proposed Sale Value

    The proposed sale is valued at approximately $1,836,640.00, representing a substantial transaction for an insider.

  • Pattern of Recent Sales

    This proposed sale follows previous dispositions by Mr. Shlevin, who sold 228,706 shares for $1,395,405.21 in the past three months.


auto_awesomeAnalysis

This Form 144 filing signals a significant intent to sell by Director Harold Shlevin, with the proposed transaction valued at $1.84 million. This amount is notable relative to the company's market capitalization. The filing also reveals that Mr. Shlevin has already sold an additional $1.40 million worth of shares in the preceding three months, suggesting a sustained pattern of reducing his stake. While the sale is likely pre-planned given the adoption date, the cumulative value of these dispositions could be perceived negatively by investors as it represents a substantial reduction in insider ownership.

At the time of this filing, GALT was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $244.1M. The 52-week trading range was $1.07 to $7.13. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed GALT - Latest Insights

GALT
Mar 31, 2026, 4:11 PM EDT
Filing Type: S-3
Importance Score:
9
GALT
Mar 31, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
GALT
Mar 31, 2026, 7:50 AM EDT
Filing Type: 10-K
Importance Score:
7
GALT
Mar 17, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
7
GALT
Jan 06, 2026, 11:10 AM EST
Filing Type: 144
Importance Score:
7
GALT
Jan 02, 2026, 8:27 AM EST
Filing Type: 144
Importance Score:
7